Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022

Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022

Supernus Prescription drugs, Inc.

ROCKVILLE, Md., Could 02, 2022 (Globe NEWSWIRE) — Supernus Prescription drugs, Inc. (Nasdaq: SUPN), a biopharmaceutical enterprise focused on creating and commercializing products and solutions for the therapy of central nervous process (CNS) disorders, these days declared that the Enterprise expects to report economical and organization final results for the to start with quarter of 2022 right after the market place closes on Monday, May well 9, 2022.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a meeting phone to current the to start with quarter 2022 monetary and enterprise outcomes on Monday, Might 9, 2022 at 4:30 p.m. ET. Pursuing management’s well prepared remarks and discussion of organization outcomes, the call will be open for inquiries.

A are living webcast will be readily available in the Activities & Presentations segment of the Supernus web page at

You should refer to the data down below for meeting contact dial-in info. Callers need to dial in approximately 10 minutes prior to the begin of the simply call.

Convention dial-in:

(877) 288-1043

Global dial-in:

(970) 315-0267

Conference ID:


Conference Phone Name:

Supernus Prescribed drugs Very first Quarter 2022 Final results Conference Get in touch with

Next the reside call, a replay will be readily available on the Company’s internet site,, in the Trader Relations section. The webcast will be available on the Company’s web page for 60 times next the stay connect with.

About Supernus Prescribed drugs, Inc.

Supernus Prescribed drugs is a biopharmaceutical firm concentrated on producing and commercializing goods for the treatment method of central nervous technique (CNS) ailments.

Our diverse neuroscience portfolio incorporates accepted treatment plans for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, serious sialorrhea, dyskinesia in PD individuals getting levodopa-based mostly therapy, and drug-induced extrapyramidal reactions in grownup individuals. We are producing a wide range of novel CNS item candidates together with new prospective treatment options for hypomobility in PD, epilepsy, despair, and other CNS disorders.

For additional information, remember to check out


Jack A. Khattar, President and CEO
Tim Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591


Investor Speak to:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767
Electronic mail: [email protected]